The only tissue-free for ctDNA detection for early-stage
colorectal, breast, and lung cancers.1-5
Interrogate thousands of genomic and epigenomic signals to achieve
high sensitivity without tissue dependency.1,2
Results in <10 days.1*
Detect MRD within
3 to 13 weeks after
curative intent therapy¹
Monitor ctDNA to help predict recurrence¹
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Product availability may vary depending on region.
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
*Average turnaround time from sample receipt to results.